TGA Approval Of Low Dose Cannabidiol, page-40

On 25 September 2020 Tim Boreham in an article titled Drawbacks of the TGA’s cannabis changes for listed pot stocks.
made these salient points:
CBD formulations still need to be backed by clinical data. The Australian Register of Therapeutic Goods (ARTG), requires "high quality" clinical evidence. Producers will need to produce similar clinical data as for a prescription CBD medicine.
Availability doesn’t guarantee advocacy. The relationship with the pharmacist is going to be very important. Just because it’s available it doesn’t mean they are going to support it,"
Low dosage could be ineffective. The 60 milligrams limit is likely to be ineffectual for certain conditions. The dosages will only be suitable for pain management and insomnia.
Products may not compete with non-CBD alternatives. Then there’s the issue of cost which needs to stack up against non-CBD alternatives.
The saturated Australian market. The Australian cannabis market is saturated with many local companies vying for a share of a limited market. There is also the threat that overseas companies from Canada and UK may enter the Australian market.